Literature DB >> 19118973

Assessing risk communication in breast cancer: are continuous measures of patient knowledge better than categorical?

Jeffrey Belkora1, Dan H Moore, David W Hutton.   

Abstract

OBJECTIVE: To compare the performance of categorical and continuous measures of patient knowledge in the context of risk communication about breast cancer, in terms of statistical and clinical significance as well as efficiency.
METHODS: Twenty breast cancer patients provided estimates of 10-year mortality risk before and after their oncology visit. The oncologist reviewed risk estimates from Adjuvant!, a well-validated and commonly used prognostic model. Using the Adjuvant! estimates as a gold standard, we calculated how accurate the patient estimates were before and after the visit. We used three novel continuous measures of patient accuracy, the absolute bias, Brier, and Kullback-Leibler scores, and compared them to a categorical measure in terms of sensitivity to intervention effects. We also calculated the sample size required to replicate the primary study using the categorical and continuous measures, as a means of comparing efficiency.
RESULTS: In this sample, the Kullback-Leibler measure was most sensitive to the intervention effects (p=0.004), followed by Brier and absolute bias (both p=0.011), and finally the categorical measure (0.125). The sample size required to replicate the primary study was 18 for the Kullback-Leibler measure, 23 for absolute bias and Brier, and 37 for the categorical measure.
CONCLUSIONS: The continuous measures led to more efficient sample sizes and to rejection of the null hypothesis of no intervention effect. However, the difference in sensitivity of the continuous measures was not statistically significant, and the performance of the categorical measure depends on the researcher's categorical cutoff for accuracy. Continuous measures of patient accuracy may be more sensitive and efficient, while categorical measures may be more clinically relevant. PRACTICE IMPLICATIONS: Researchers and others interested in assessing the accuracy of patient knowledge should weigh the trade-offs between clinical relevance and statistical significance while designing or evaluating risk communication studies.

Entities:  

Mesh:

Year:  2009        PMID: 19118973      PMCID: PMC2763188          DOI: 10.1016/j.pec.2008.11.012

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  12 in total

1.  A tailored intervention to aid decision-making about hormone replacement therapy.

Authors:  Colleen M McBride; Lori A Bastian; Susan Halabi; Laura Fish; Isaac M Lipkus; Hayden B Bosworth; Barbara K Rimer; Ilene C Siegler
Journal:  Am J Public Health       Date:  2002-07       Impact factor: 9.308

Review 2.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

3.  A randomized trial of a computerized versus an audio-booklet decision aid for women considering post-menopausal hormone replacement therapy.

Authors:  Alaa Rostom; Annette O'Connor; Peter Tugwell; George Wells
Journal:  Patient Educ Couns       Date:  2002-01

4.  How well can physicians estimate mortality in a medical intensive care unit?

Authors:  D K McClish; S H Powell
Journal:  Med Decis Making       Date:  1989 Apr-Jun       Impact factor: 2.583

5.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Authors:  Ivo A Olivotto; Chris D Bajdik; Peter M Ravdin; Caroline H Speers; Andrew J Coldman; Brian D Norris; Greg J Davis; Stephen K Chia; Karen A Gelmon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

6.  [Making a decision about hormone replacement therapy. A randomized controlled trial].

Authors:  S Dodin; F Légaré; G Daudelin; J Tetroe; A O'Connor
Journal:  Can Fam Physician       Date:  2001-08       Impact factor: 3.275

7.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

Authors:  P M Ravdin; L A Siminoff; G J Davis; M B Mercer; J Hewlett; N Gerson; H L Parker
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

8.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

Authors:  M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

9.  A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial.

Authors:  M Man-Son-Hing; A Laupacis; A M O'Connor; J Biggs; E Drake; E Yetisir; R G Hart
Journal:  JAMA       Date:  1999-08-25       Impact factor: 56.272

10.  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

Authors: 
Journal:  Arch Intern Med       Date:  1994-07-11
View more
  2 in total

1.  Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?

Authors:  Jeffrey K Belkora; David W Hutton; Dan H Moore; Laura A Siminoff
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

2.  Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.

Authors:  Jeffrey K Belkora; Hope S Rugo; Dan H Moore; David W Hutton; Daniel F Chen; Laura J Esserman
Journal:  BMC Cancer       Date:  2009-04-28       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.